Spina Bifida Treatment Market to Reach $3.25 Billion by 2035

Spina bifida treatment market was valued at $1.88 billion in 2025 and is projected to reach $3.25 billion by 2035, growing at a CAGR of 5.62% during the forecast period (2026–2035). The increasing prevalence of neural tube defects and rising awareness regarding early diagnosis and treatment are significantly driving market growth. Spina bifida, a congenital birth defect affecting the spinal cord, requires lifelong medical care, including surgical interventions, pharmacological treatments, and rehabilitation support. Advancements in fetal surgery techniques and growing adoption of minimally invasive procedures are further supporting treatment outcomes and expanding the market landscape. The integration of robotics and neurostimulation technologies into rehabilitation is also improving patient mobility and quality of life, thereby strengthening demand for advanced therapeutic solutions globally.

Browse the full report description of “Spina Bifida Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Surgical Treatment, Pharmacological Treatment, Assistive & Supportive Care), By Type (Myelomeningocele, Meningocele, Spina Bifida Occulta), By End-User (Hospitals & Specialty Clinics, Rehabilitation Centers, Homecare Providers), By Technology Type (Open Fetal Surgery, Minimally Invasive Fetal Surgery (Fetoscopic), Conventional Neurosurgical Procedures, Advanced Rehabilitation Technologies (Robotics, Neurostimulation)), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/spina-bifida-treatment-market

Rising Burden of Neural Tube Defects Driving Treatment Demand

According to the World Health Organization, neural tube defects affect approximately 300,000 newborns globally each year, highlighting the significant healthcare burden associated with congenital disorders. Additionally, the Centers for Disease Control and Prevention reports that spina bifida occurs in approximately 1,500–2,000 births annually in the United States. Increasing government initiatives promoting folic acid supplementation and early prenatal screening are improving diagnosis rates, thereby expanding the treated patient pool. This rising incidence, combined with growing access to specialized healthcare services, is directly contributing to the expansion of the spina bifida treatment market.

Advancements in Paediatric and Specialized Healthcare Infrastructure Supporting Growth

In developed regions such as North America and Europe, advancements in paediatric neurosurgery and rehabilitation infrastructure are accelerating market growth. According to the European Commission, healthcare expenditure across EU member states continues to rise, with increasing investments in specialized care for rare and congenital disorders. Similarly, the U.S. Food and Drug Administration has been actively supporting innovations in medical devices and surgical techniques, including fetal surgical interventions and neurostimulation technologies. These developments are enabling improved treatment outcomes and expanding access to advanced therapies, particularly in hospital and specialty clinic settings.

Key Leaders Transforming the Spina Bifida Treatment Market

The key players in the spina bifida treatment market include Medtronic plc, Integra LifeSciences, B. Braun SE, Coloplast A/S, Boston Scientific Corporation, among others. These companies are focusing on advanced biologics, gene therapy approaches, and innovative surgical technologies to enhance treatment outcomes and address unmet medical needs.

• In March 2026, Medtronic entered into a strategic distribution agreement with Merit Medical Systems to offer the FDA-cleared ViaVerte™ system, a minimally invasive basivertebral nerve ablation (BVNA) treatment for chronic vertebrogenic lower-back pain. The ViaVerte™ system features a physician-controlled steerable mechanism for precise nerve targeting, enhancing procedural accuracy and patient outcomes. This collaboration strengthens Medtronic’s pain management portfolio and expands access to advanced, implant-free treatment options, supporting the growing demand for minimally invasive chronic pain therapies.
• In February 2026, Medtronic announced that the U.S. Food and Drug Administration granted Premarket Approval (PMA) for its INFUSE™ Bone Graft for use in one- and two-level Transforaminal Lumbar Interbody Fusion (TLIF) procedures. This approval expands the application of INFUSE™ across ALIF, OLIF, and TLIF procedures, making it the only growth factor bone graft approved for multi-level spine fusion. The approval was supported by strong clinical evidence demonstrating over 90% fusion rates and improved healing outcomes, reinforcing Medtronic’s position in advanced spinal treatment solutions.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Treatment Type
• Type
• End-User
• Technology Type
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape – Medtronic plc, Integra LifeSciences, B. Braun SE, Coloplast A/S, Boston Scientific Corporation, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Spina Bifida Treatment Market Segmentation (360° View)

By Treatment Type

• Surgical Treatment
• Pharmacological Treatment
• Assistive & Supportive Care

By Type

• Myelomeningocele
• Meningocele
• Spina Bifida Occulta

By End-User

• Hospitals & Specialty Clinics
• Rehabilitation Centers
• Homecare Providers

By Technology Type

• Open Fetal Surgery
• Minimally Invasive Fetal Surgery (Fetoscopic)
• Conventional Neurosurgical Procedures
• Advanced Rehabilitation Technologies (Robotics, Neurostimulation)

Global Spina Bifida Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/spina-bifida-treatment-market